ArticleEuropean radiology2024
Radiomics and machine learning for renal tumor subtype assessment using multiphase computed tomography in a multicenter setting.
Article in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Artificial intelligence in the radiologic diagnosis of major urological cancers: a meta-analysis.World journal of urology · 2026Pooled it
- Diagnostic performance of artificial intelligence in detection of renal cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Review
- The Central Role of Imaging in Renal Cell Carcinoma: A Comprehensive Review of Tumor Aggressiveness, Histology, and Radiomics.Cancers · 2026Review
- Radiomics analysis of CT imaging for predicting MIT family translocation renal cell carcinoma: a multicenter retrospective clinical study.BMC cancer · 2026Article
- Submanifold sparse convolutional networks for automated 3D segmentation of kidneys and kidney tumours in computed tomography.Scientific reports · 2026Article
- CT-Based Radiomics in the Characterization of Solid Renal Tumors: A Systematic Review.Cancers · 2026Review
- Multimodal deep learning model for multiclass classification of renal tumors.NPJ digital medicine · 2026Article
- Noninvasive prediction of occult pT3a upstaging in localized ccRCC with radiogenomic insights and prognostic relevance.NPJ precision oncology · 2026Article
- Differentiation of pulmonary tuberculosis from non-tuberculous solid lung lesions using radiomics and clinical-semantic features on contrast-enhanced CT.Frontiers in medicine · 2026Article
- Trends in artificial intelligence and machine learning for renal cancer.Discover oncology · 2025Article
- State of the art review of AI in renal imaging.Abdominal radiology (New York) · 2025Review
- Advances in renal cancer: diagnosis, treatment, and emerging technologies.La Radiologia medica · 2025Review
- Computed Tomography-Based Radiomics Diagnostic Model for Fat-Poor Small Renal Tumor Subtypes.Diagnostics (Basel, Switzerland) · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo distinguish histological subtypes of renal tumors using radiomic features and machine learning (ML) based on multiphase computed tomography (CT). MATERIAL AND
methodsPatients who underwent surgical treatment for renal tumors at two tertiary centers from 2012 to 2022 were included retrospectively. Preoperative arterial (corticomedullary) and venous (nephrogenic) phase CT scans from these centers, as well as from external imaging facilities, were manually segmented, and standardized radiomic features were extracted. Following preprocessing and addressing the class imbalance, a ML algorithm based on extreme gradient boosting trees (XGB) was employed to predict renal tumor subtypes using 10-fold cross-validation. The evaluation was conducted using the multiclass area under the receiver operating characteristic curve (AUC). Algorithms were trained on data from one center and independently tested on data from the other center.
resultsThe training cohort comprised n = 297 patients (64.3% clear cell renal cell cancer [RCC], 13.5% papillary renal cell carcinoma (pRCC), 7.4% chromophobe RCC, 9.4% oncocytomas, and 5.4% angiomyolipomas (AML)), and the testing cohort n = 121 patients (56.2%/16.5%/3.3%/21.5%/2.5%). The XGB algorithm demonstrated a diagnostic performance of AUC = 0.81/0.64/0.8 for venous/arterial/combined contrast phase CT in the training cohort, and AUC = 0.75/0.67/0.75 in the independent testing cohort. In pairwise comparisons, the lowest diagnostic accuracy was evident for the identification of oncocytomas (AUC = 0.57-0.69), and the highest for the identification of AMLs (AUC = 0.9-0.94)
conclusionRadiomic feature analyses can distinguish renal tumor subtypes on routinely acquired CTs, with oncocytomas being the hardest subtype to identify. CLINICAL RELEVANCE STATEMENT: Radiomic feature analyses yield robust results for renal tumor assessment on routine CTs. Although radiologists routinely rely on arterial phase CT for renal tumor assessment and operative planning, radiomic features derived from arterial phase did not improve the accuracy of renal tumor subtype identification in our cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.